In line with the above results, we found that baseline FGF21 was not able to predict the remission of NAFLD or suspected NASH at follow-up, suggesting FGF21 might not be a potential biomarker for the prognosis of NAFLD patients. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.